In patients with Multiple Endocrine Neoplasia Type 2A who develop advanced, progressive medullary thyroid carcinoma (MTC) with significant tumor burden or symptomatic metastatic disease, systemic therapy becomes the central treatment consideration.
This protocol applies to patients with MEN2A presenting with advanced MTC that is progressive per RECIST criteria, symptomatic metastatic disease, or significant tumor burden — where systemic intervention is indicated.
First-line systemic therapy involves a single-agent tyrosine kinase inhibitor with dual activity against RET and VEGFR targets. The full regimen — including agent selection criteria, sequencing, and monitoring — is detailed in the complete protocol.
In patients with significant tumor burden and symptomatic or progressive metastatic disease according to RECIST treatment with TKIs targeting both RET and VEGFR tyrosine kinases should be considered as systemic therapy.
The TKIs vandetanib or cabozantinib can be used as single-agent first-line systemic therapy in patients with advanced progressive MTC.
View source ↗